Report : Asia Pacific Epilepsy Market Forecast to 2030 - Regional Analysis - by Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First Generation Drugs, Second Generation Drugs, and Third Generation Drugs), Age Group (Adult and Children), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

At 4.6% CAGR, Asia Pacific Epilepsy Market is Projected to be Worth US$ 3,143.44 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific epilepsy market was valued at US$ 2,200.92 million in 2022 and is expected to reach US$ 3,143.44 million by 2030, registering a CAGR of 4.6% from 2022 to 2030. Increasing investments in development of epilepsy therapies and rising prevalence of epilepsy are among the critical factors attributed to drive the Asia Pacific epilepsy market growth.

The healthcare sector is transforming with rapid technological developments and innovation, enhancing healthcare services and quality of care. The epilepsy market is characterized by the presence of several small and large companies and organizations implementing various growth strategies. The availability of funding enables companies and organizations to boost production levels, expand into new markets, invest in new/improved technologies, and allocate more resources to R&D. A few of the notable investments in the epilepsy market, contributing to the market progress, have been mentioned below.

  • In May 2023, Japan's JCR Pharmaceuticals secured US$ 505.5 million from Angelini, a family-owned Italian pharmaceutical group, for the development of a new anti-epileptic treatment capable of penetrating the blood-brain barrier.
  • In 2023, the Medical Research Future Fund (MRRF) awarded a total of US$ 1.37 million to researchers at Monash University in Australia for three epilepsy-related projects. Digital tools for seizures and a recently created saliva ketone testing equipment for use at home are among the research projects.

Therefore, increasing investments in the development of advanced treatments propels the growth of the epilepsy market.

On the contrary, recall of products hampers the growth of Asia Pacific epilepsy market.

Based on type, the Asia Pacific epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held 51.0% market share in 2022, amassing US$ 1,123.09 million. It is projected to garner US$ 1,654.41 million by 2030 to register 5.0% CAGR during 2022-2030.

In terms of route of administration, the Asia Pacific epilepsy market is categorized into oral, parenteral, and others. The oral segment held 70.2% share of Asia Pacific epilepsy market in 2022, amassing US$ 1,545.10 million. It is anticipated to garner US$ 2,295.34 million by 2030 to expand at 5.1% CAGR during 2022-2030.

By treatment type, the Asia Pacific epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held 42.6% share of Asia Pacific epilepsy market in 2022, amassing US$ 938.37 million. It is projected to garner US$ 1,386.78 million by 2030 to expand at 5.0% CAGR from 2022 to 2030.

Based on age group, the Asia Pacific epilepsy market is bifurcated into adult and children. The adult segment held 80.0% share of Asia Pacific epilepsy market in 2022, amassing US$ 1,761.49 million. It is predicted to garner US$ 2,598.40 million by 2030 to expand at 5.0% CAGR between 2022 and 2030.

In terms of distribution channel, the Asia Pacific epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held 51.0% share of Asia Pacific epilepsy market in 2022, amassing US$ 1,122.70 million. It is projected to garner US$ 1,551.72 million by 2030 to expand at 4.1% CAGR from 2022 to 2030.

By country, the Asia Pacific epilepsy market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 25.3% share of Asia Pacific epilepsy market in 2022. It was assessed at US$ 556.61 million in 2022 and is likely to hit US$ 825.21 million by 2030, registering a CAGR of 5.0% during 2022-2030.

Key players operating in the Asia Pacific epilepsy market are Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS, among others.

In January 2024, Eisai Co Ltd announced that the Japanese Ministry of Health, Labour and Welfare has approved its Fycompa's (perampanel) injection formulation in Japan. The product is approved as an alternative therapy when oral administration is temporarily impossible. For instance, during surgery, the risks of seizures are associated with interruption of administration by taking the drug orally. This concern has allowed the company to develop an injection formulation and offer a new form of the drug along with the tablet and fine granules, which are already available in Japan.

In October 2022, GliaPharm, a company co-founded by Professor Pierre Magistretti that develops therapies for neurological and psychological disorders, and UCB collaborated on a drug development project. As part of the partnership, GliaPharm will validate a number of therapeutic targets using their exclusive GliaX technology platform, which will help UCB SA in its quest to find epilepsy-specific medications.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com

 

Download Free PDF Brochure